TP53 and Miyoshi myopathy: Although there is ongoing debate about whether bi-allelic TP53 inactivation carries additional risk beyond del(17p) alone [9,29], our study confirmed that del(17p) combined with another HRCA was associated with adverse outcomes in MM.